Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

V. Adamo, M. Iorfida, E. Montalto, V. Festa, C. Garipoli, A. Scimone, M. Zanghì, N. Caristi

Research output: Contribution to journalArticle

Abstract

The treatment with aromatase inhibitors (AIs) and fulvestrant has been demonstrated to be active in a proportion of tamoxifen-resistant breast cancer patients, obtaining, in some cases, a long-term control of tumor growth. Results from clinical trials indicate that treatment with fulvestrant might either precede or follow AIs. However, the AIs are now replacing tamoxifen as first-line advanced and adjuvant therapies, and thus, other options following tamoxifen failure are required. Fulvestrant may be effective in this setting, even if there is also evidence of a lack of cross-resistance between nonsteroidal and steroidal AIs, resulting in the potential use of steroidal AIs following nonsteroidal AI failure and vice versa. Resistance mechanisms to these therapies appear to be related to a cross talk between estrogen receptor (ER) and growth factor-signaling cascades. Novel therapeutic approaches for ER+ patients, which combine hormonal agents and signal transduction inhibitors, have been developed to overcoming resistance. Several trials are now investigating signal transduction inhibitors combined with endocrine agents. This approach might provide efficient treatments and delay the onset of antihormone resistance, thereby significantly improving patient's survival.

Original languageEnglish
JournalAnnals of Oncology
Volume18
Issue numberSUPPL. 6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Aromatase Inhibitors
Tamoxifen
Breast Neoplasms
Estrogen Receptors
Signal Transduction
Therapeutics
Intercellular Signaling Peptides and Proteins
Clinical Trials
Survival
Growth
fulvestrant
Neoplasms

Keywords

  • Metastatic breast cancer
  • New strategies
  • Overview
  • Resistance
  • Tamoxifen
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Cancer Research

Cite this

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. / Adamo, V.; Iorfida, M.; Montalto, E.; Festa, V.; Garipoli, C.; Scimone, A.; Zanghì, M.; Caristi, N.

In: Annals of Oncology, Vol. 18, No. SUPPL. 6, 06.2007.

Research output: Contribution to journalArticle

Adamo, V, Iorfida, M, Montalto, E, Festa, V, Garipoli, C, Scimone, A, Zanghì, M & Caristi, N 2007, 'Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients', Annals of Oncology, vol. 18, no. SUPPL. 6. https://doi.org/10.1093/annonc/mdm225
Adamo, V. ; Iorfida, M. ; Montalto, E. ; Festa, V. ; Garipoli, C. ; Scimone, A. ; Zanghì, M. ; Caristi, N. / Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. In: Annals of Oncology. 2007 ; Vol. 18, No. SUPPL. 6.
@article{c4e070d63ff74f908ee6775254a6f1de,
title = "Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients",
abstract = "The treatment with aromatase inhibitors (AIs) and fulvestrant has been demonstrated to be active in a proportion of tamoxifen-resistant breast cancer patients, obtaining, in some cases, a long-term control of tumor growth. Results from clinical trials indicate that treatment with fulvestrant might either precede or follow AIs. However, the AIs are now replacing tamoxifen as first-line advanced and adjuvant therapies, and thus, other options following tamoxifen failure are required. Fulvestrant may be effective in this setting, even if there is also evidence of a lack of cross-resistance between nonsteroidal and steroidal AIs, resulting in the potential use of steroidal AIs following nonsteroidal AI failure and vice versa. Resistance mechanisms to these therapies appear to be related to a cross talk between estrogen receptor (ER) and growth factor-signaling cascades. Novel therapeutic approaches for ER+ patients, which combine hormonal agents and signal transduction inhibitors, have been developed to overcoming resistance. Several trials are now investigating signal transduction inhibitors combined with endocrine agents. This approach might provide efficient treatments and delay the onset of antihormone resistance, thereby significantly improving patient's survival.",
keywords = "Metastatic breast cancer, New strategies, Overview, Resistance, Tamoxifen, Treatment",
author = "V. Adamo and M. Iorfida and E. Montalto and V. Festa and C. Garipoli and A. Scimone and M. Zangh{\`i} and N. Caristi",
year = "2007",
month = "6",
doi = "10.1093/annonc/mdm225",
language = "English",
volume = "18",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

AU - Adamo, V.

AU - Iorfida, M.

AU - Montalto, E.

AU - Festa, V.

AU - Garipoli, C.

AU - Scimone, A.

AU - Zanghì, M.

AU - Caristi, N.

PY - 2007/6

Y1 - 2007/6

N2 - The treatment with aromatase inhibitors (AIs) and fulvestrant has been demonstrated to be active in a proportion of tamoxifen-resistant breast cancer patients, obtaining, in some cases, a long-term control of tumor growth. Results from clinical trials indicate that treatment with fulvestrant might either precede or follow AIs. However, the AIs are now replacing tamoxifen as first-line advanced and adjuvant therapies, and thus, other options following tamoxifen failure are required. Fulvestrant may be effective in this setting, even if there is also evidence of a lack of cross-resistance between nonsteroidal and steroidal AIs, resulting in the potential use of steroidal AIs following nonsteroidal AI failure and vice versa. Resistance mechanisms to these therapies appear to be related to a cross talk between estrogen receptor (ER) and growth factor-signaling cascades. Novel therapeutic approaches for ER+ patients, which combine hormonal agents and signal transduction inhibitors, have been developed to overcoming resistance. Several trials are now investigating signal transduction inhibitors combined with endocrine agents. This approach might provide efficient treatments and delay the onset of antihormone resistance, thereby significantly improving patient's survival.

AB - The treatment with aromatase inhibitors (AIs) and fulvestrant has been demonstrated to be active in a proportion of tamoxifen-resistant breast cancer patients, obtaining, in some cases, a long-term control of tumor growth. Results from clinical trials indicate that treatment with fulvestrant might either precede or follow AIs. However, the AIs are now replacing tamoxifen as first-line advanced and adjuvant therapies, and thus, other options following tamoxifen failure are required. Fulvestrant may be effective in this setting, even if there is also evidence of a lack of cross-resistance between nonsteroidal and steroidal AIs, resulting in the potential use of steroidal AIs following nonsteroidal AI failure and vice versa. Resistance mechanisms to these therapies appear to be related to a cross talk between estrogen receptor (ER) and growth factor-signaling cascades. Novel therapeutic approaches for ER+ patients, which combine hormonal agents and signal transduction inhibitors, have been developed to overcoming resistance. Several trials are now investigating signal transduction inhibitors combined with endocrine agents. This approach might provide efficient treatments and delay the onset of antihormone resistance, thereby significantly improving patient's survival.

KW - Metastatic breast cancer

KW - New strategies

KW - Overview

KW - Resistance

KW - Tamoxifen

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=35748948098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748948098&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm225

DO - 10.1093/annonc/mdm225

M3 - Article

C2 - 17591833

AN - SCOPUS:35748948098

VL - 18

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 6

ER -